Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANITA KOHLI

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1619189800
CMS profile
494839
Location
CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$164,175.61

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANITA KOHLI

NPI 1619189800 · CMS profile ID 494839

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANITA KOHLI, NPI 1619189800, CMS profile ID 494839. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANITA KOHLI, NPI 1619189800, CMS profile ID 494839. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANITA KOHLI, NPI 1619189800, CMS profile ID 494839, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $164,175.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Madrigal Pharmaceuticals $27.2105/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248278574 CMS
Madrigal Pharmaceuticals $89.8805/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248278576 CMS
Gilead Sciences, Inc. $18.8104/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234540999 CMS
Madrigal Pharmaceuticals $140,000.0004/29/2025 Grant No dispute reported Delay: No
Change: NEW
06/30/2026 1248278572 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.7104/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231802510 CMS
Gilead Sciences, Inc. $139.6704/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234377750 CMS
Ipsen Biopharmaceuticals, Inc $15.6404/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208861038 CMS
Gilead Sciences, Inc. $800.0004/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234359505 CMS
Intercept Pharmaceuticals, Inc. $18.6504/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249868677 CMS
Ipsen Biopharmaceuticals, Inc $18.2003/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208861034 CMS
Gilead Sciences, Inc. $19.4703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234533919 CMS
Invivyd Inc $24.0203/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240484864 CMS
Ipsen Biopharmaceuticals, Inc $61.5403/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208861049 CMS
Gilead Sciences, Inc. $25.7203/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234468281 CMS
Madrigal Pharmaceuticals $41.5203/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248278570 CMS
ABBVIE INC. $13.8402/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202221127 CMS
Madrigal Pharmaceuticals $47.8202/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248278568 CMS
Madrigal Pharmaceuticals $39.4001/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248278566 CMS
Madrigal Pharmaceuticals $2,115.0001/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248278564 CMS
Ipsen Biopharmaceuticals, Inc $23.6401/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208861031 CMS
Gilead Sciences, Inc. $5.5501/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234600838 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,478.44 41
PY2020 $3,526.31 40
PY2021 $1,555.98 55
PY2022 $15,025.09 54
PY2023 $3,848.01 37
PY2024 $9,772.31 55
PY2025 $164,175.61 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,143,993.05 885
PY2024 Recipient $726.56 1
PY2024 Principal investigator $4,741,777.65 291
PY2023 Recipient $620.01 1
PY2023 Principal investigator $881,751.52 176
PY2022 Recipient $21,000.00 2
PY2022 Principal investigator $1,874,204.60 222
PY2021 Recipient $666.19 5
PY2021 Principal investigator $4,278,092.48 928
PY2020 Recipient $150,049.96 2
PY2020 Principal investigator $3,452,166.39 282
PY2019 Recipient $67.00 1
PY2019 Principal investigator $2,685,802.13 181

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

885 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $136.05 12/31/2025 Non-covered Recipient Entity
Arizona Clinical Trials
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants with Mild and Moderate Hepatic Impairment No dispute reported 06/30/2026 1232938788
Principal investigator 1 Eli Lilly and Company $5,634.00 12/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 No dispute reported 06/30/2026 1187881826
Principal investigator 1 F. Hoffmann-La Roche AG $8,881.65 12/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665868
Principal investigator 1 F. Hoffmann-La Roche AG $71,702.55 12/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665873
Principal investigator 1 Madrigal Pharmaceuticals $13,224.40 12/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248254768
Principal investigator 1 Madrigal Pharmaceuticals $29.40 12/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248254772
Principal investigator 1 Boehringer Ingelheim International GmbH $3,613.40 12/19/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685015
Principal investigator 1 Boehringer Ingelheim International GmbH $839.16 12/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699610
Principal investigator 1 Boehringer Ingelheim International GmbH $5,100.20 12/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699634
Principal investigator 1 Boehringer Ingelheim International GmbH $3,675.28 12/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699642
Principal investigator 1 Boehringer Ingelheim International GmbH $3,188.08 12/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699656
Principal investigator 1 Boehringer Ingelheim International GmbH $839.16 12/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699658
Principal investigator 1 Hoffmann-La Roche Limited $3,044.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211665897
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $19,853.10 12/19/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285897
Principal investigator 1 Madrigal Pharmaceuticals $11,734.89 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254489
Principal investigator 1 Madrigal Pharmaceuticals $4,036.50 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254514
Principal investigator 1 Madrigal Pharmaceuticals $100.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254518
Principal investigator 1 Madrigal Pharmaceuticals $5,467.50 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254521
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254525
Principal investigator 1 Madrigal Pharmaceuticals $555.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254529
Principal investigator 1 Madrigal Pharmaceuticals $1,917.34 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254533
Principal investigator 1 Madrigal Pharmaceuticals $50.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254538
Principal investigator 1 Madrigal Pharmaceuticals $3,037.50 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254542
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184278784
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,159.75 12/18/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220802006
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 12/17/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699568
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 12/17/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699570
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 12/17/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699572
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 12/17/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699574
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187881828
Principal investigator 1 Eli Lilly and Company $934.02 12/17/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187882076
Principal investigator 1 F. Hoffmann-La Roche AG $1,936.00 12/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665866
Principal investigator 1 Madrigal Pharmaceuticals $2,935.40 12/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254168
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,600.00 12/15/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801976
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,170.40 12/15/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801978
Principal investigator 1 Boehringer Ingelheim International GmbH $131.04 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699510
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699512
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699514
Principal investigator 1 Boehringer Ingelheim International GmbH $294.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699516
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699518
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699520
Principal investigator 1 Boehringer Ingelheim International GmbH $147.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699522
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699524
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699526
Principal investigator 1 Boehringer Ingelheim International GmbH $15,000.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699528
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699530
Principal investigator 1 Boehringer Ingelheim International GmbH $112.89 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699532
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699534
Principal investigator 1 Boehringer Ingelheim International GmbH $131.04 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699536
Principal investigator 1 Boehringer Ingelheim International GmbH $147.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699538
Principal investigator 1 Boehringer Ingelheim International GmbH $294.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699540
Principal investigator 1 Boehringer Ingelheim International GmbH $294.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699542
Principal investigator 1 Boehringer Ingelheim International GmbH $13,000.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699544
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699546
Principal investigator 1 Boehringer Ingelheim International GmbH $5,725.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699548
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699550
Principal investigator 1 Boehringer Ingelheim International GmbH $141.12 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699552
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699554
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699556
Principal investigator 1 Boehringer Ingelheim International GmbH $147.00 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699558
Principal investigator 1 Boehringer Ingelheim International GmbH $131.04 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699560
Principal investigator 1 Boehringer Ingelheim International GmbH $112.89 12/11/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699562
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $1,100.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285881
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $113.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285883
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $107.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285885
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $2,240.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285887
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $507.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285889
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $452.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285891
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $113.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285893
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $391.00 12/11/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285895
Principal investigator 1 Madrigal Pharmaceuticals $4,629.83 12/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253978
Principal investigator 1 Madrigal Pharmaceuticals $14,377.50 12/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253990
Principal investigator 1 Madrigal Pharmaceuticals $405.00 12/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,244.25 12/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,759.40 12/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274242
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 12/10/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220814045
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/05/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699600
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/05/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699618
Principal investigator 1 Boehringer Ingelheim International GmbH $120.00 12/05/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699620
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 12/05/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699638
Principal investigator 1 Boehringer Ingelheim International GmbH $84.00 12/05/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699644
Principal investigator 1 Boehringer Ingelheim International GmbH $84.00 12/05/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699660
Principal investigator 1 Madrigal Pharmaceuticals $16,640.00 12/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253579
Principal investigator 1 Madrigal Pharmaceuticals $3,406.00 12/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253583
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685017
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685019
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685021
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685023
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685025
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685027
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685029
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 12/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685031
Principal investigator 1 Hoffmann-La Roche Limited $17,168.00 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211665901
Principal investigator 1 Madrigal Pharmaceuticals $1,380.40 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248253418
Principal investigator 1 Madrigal Pharmaceuticals $105.00 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248253423
Principal investigator 1 Madrigal Pharmaceuticals $7,425.69 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184268901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,256.10 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184268903
Principal investigator 1 Boehringer Ingelheim International GmbH $270.95 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699602
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699604
Principal investigator 1 Boehringer Ingelheim International GmbH $80.64 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699606
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699608
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699612
Principal investigator 1 Boehringer Ingelheim International GmbH $80.64 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699614
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699616
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699622
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699624
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699626
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699628
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699630
Principal investigator 1 Boehringer Ingelheim International GmbH $80.64 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699632
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699636
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699640
Principal investigator 1 Boehringer Ingelheim International GmbH $296.35 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699646
Principal investigator 1 Boehringer Ingelheim International GmbH $270.95 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699648
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699650
Principal investigator 1 Boehringer Ingelheim International GmbH $131.04 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699652
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699654
Principal investigator 1 Boehringer Ingelheim International GmbH $270.95 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699662
Principal investigator 1 Boehringer Ingelheim International GmbH $296.35 12/03/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699664
Principal investigator 1 ModernaTX, Inc. $136.60 12/02/2025 Non-covered Recipient Entity
LiverHealth II DBA AZ ClinTrials
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999159
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694621
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694623
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694625
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694627
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694629
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694631
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766378
Principal investigator 1 F. Hoffmann-La Roche AG $37,912.05 12/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665878
Principal investigator 1 ModernaTX, Inc. $410.40 12/01/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975885
Principal investigator 1 Boehringer Ingelheim International GmbH $3,613.40 11/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684985
Principal investigator 1 Boehringer Ingelheim International GmbH $3,613.40 11/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684993
Principal investigator 1 Boehringer Ingelheim International GmbH $21,914.20 11/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699596
Principal investigator 1 ModernaTX, Inc. $9,168.06 11/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999061
Principal investigator 1 ModernaTX, Inc. $1,460.34 11/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999073
Principal investigator 1 ModernaTX, Inc. $23,645.84 11/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999121
Principal investigator 1 ModernaTX, Inc. $9,784.20 11/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999129
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/26/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699588
Principal investigator 1 Boehringer Ingelheim International GmbH $15,000.00 11/26/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699590
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 11/26/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699592
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 11/26/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699594
Principal investigator 1 Boehringer Ingelheim International GmbH $13,000.00 11/26/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699598
Principal investigator 1 ModernaTX, Inc. $117.00 11/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999091
Principal investigator 1 ModernaTX, Inc. $201.60 11/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999127
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $872.00 11/25/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285873
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $678.00 11/25/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285875
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $1,629.00 11/25/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285877
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $1,356.00 11/25/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285879
Principal investigator 1 Madrigal Pharmaceuticals $9,580.29 11/25/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252972
Principal investigator 1 ModernaTX, Inc. $273.20 11/24/2025 Non-covered Recipient Entity
LiverHealth II DBA AZ ClinTrials
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999109
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $9,937.80 11/20/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 11/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,750.00 11/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $432.00 11/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 11/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263409
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699564
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 11/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699566
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699672
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 11/19/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699674
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $51,026.00 11/18/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220802004
Principal investigator 1 Madrigal Pharmaceuticals $49,622.30 11/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,716.15 11/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $635.85 11/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $660.00 11/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,835.00 11/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261081
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,185.10 11/13/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801972
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,137.00 11/13/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801974
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684977
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684979
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684981
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684987
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684989
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684995
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684997
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685005
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685007
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685011
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 11/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685013
Principal investigator 1 GlaxoSmithKline, LLC. $3,408.00 11/12/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192185662
Principal investigator 1 GlaxoSmithKline, LLC. $3,758.58 11/12/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192186964
Principal investigator 1 GlaxoSmithKline, LLC. $14,990.43 11/12/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192186969
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $3,645.00 11/07/2025 Non-covered Recipient Entity
Arizona Clinical Trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285869
Principal investigator 1 Madrigal Pharmaceuticals $729.30 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252456
Principal investigator 1 Madrigal Pharmaceuticals $585.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252460
Principal investigator 1 Madrigal Pharmaceuticals $585.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252464
Principal investigator 1 Madrigal Pharmaceuticals $1,950.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252467
Principal investigator 1 Madrigal Pharmaceuticals $2,805.40 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252500
Principal investigator 1 Madrigal Pharmaceuticals $195.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252504
Principal investigator 1 Madrigal Pharmaceuticals $4,629.83 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,482.55 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $702.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,750.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258115
Principal investigator 1 ModernaTX, Inc. $554.40 11/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999093
Principal investigator 1 ModernaTX, Inc. $117.00 11/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999099
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 11/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684983
Principal investigator 1 Boehringer Ingelheim International GmbH $4,600.40 11/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684991
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 11/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684999
Principal investigator 1 Boehringer Ingelheim International GmbH $3,997.00 11/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685001
Principal investigator 1 Boehringer Ingelheim International GmbH $3,997.00 11/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685003
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 11/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685009
Principal investigator 1 Madrigal Pharmaceuticals $1,380.40 11/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252310
Principal investigator 1 Madrigal Pharmaceuticals $17,759.00 11/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252314
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,544.95 11/03/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220802002
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694609
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694611
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694613
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694615
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694617
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694619
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766376
Principal investigator 1 ModernaTX, Inc. $1,572.30 10/30/2025 Non-covered Recipient Entity
LiverHealth II DBA AZ ClinTrials
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999157
Principal investigator 1 Ardelyx, Inc. $12,550.00 10/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults No dispute reported 06/30/2026 1247838740
Principal investigator 1 Ipsen Bioscience Inc. $140.00 10/29/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545579
Principal investigator 1 Ipsen Bioscience Inc. $525.00 10/29/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545581
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $122,545.00 10/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801986
Principal investigator 1 GlaxoSmithKline, LLC. $3,618.00 10/28/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192156558
Principal investigator 1 Boehringer Ingelheim International GmbH $2,323.00 10/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685033
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685035
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 10/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220685037
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694633
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694635
Principal investigator 1 Boehringer Ingelheim International GmbH $876.00 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694637
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694639
Principal investigator 1 Boehringer Ingelheim International GmbH $22.08 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694641
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699666
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699668
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 10/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699670
Principal investigator 1 ModernaTX, Inc. $8,823.54 10/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999103
Principal investigator 1 ModernaTX, Inc. $6,848.94 10/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999105
Principal investigator 1 ModernaTX, Inc. $4,655.48 10/24/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975907
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $1,101.60 10/23/2025 Non-covered Recipient Entity
Arizona Liver Health
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285701
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $7,000.00 10/23/2025 Non-covered Recipient Entity
Arizona Liver Health
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285703
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $1,500.00 10/23/2025 Non-covered Recipient Entity
Arizona Liver Health
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285705
Principal investigator 1 Madrigal Pharmaceuticals $7,105.06 10/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251964
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684947
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684949
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684951
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684953
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684955
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684957
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684959
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684961
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684963
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684965
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684967
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684969
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684971
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684973
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 10/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684975
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 10/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211665886
Principal investigator 1 Hoffmann-La Roche Limited $10,000.00 10/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211665890
Principal investigator 1 Hoffmann-La Roche Limited $2,783.00 10/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211665894
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $1,000.00 10/16/2025 Non-covered Recipient Entity
Arizona Liver Health
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285699
Principal investigator 1 Madrigal Pharmaceuticals $2,475.23 10/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251553
Principal investigator 1 Madrigal Pharmaceuticals $5,518.80 10/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248251562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,969.70 10/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250467
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $475.00 10/15/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801970
Principal investigator 1 Genentech, Inc. $450.00 10/13/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211665882
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $2,425.50 10/09/2025 Non-covered Recipient Entity
Arizona Liver Health
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285697
Principal investigator 1 Madrigal Pharmaceuticals $4,950.46 10/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251443
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,031.10 10/08/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801994
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,717.25 10/08/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801996
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,496.85 10/08/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801998
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,496.85 10/08/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220802000
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $940.95 10/03/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801988
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $583.20 10/03/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801990
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,040.95 10/03/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801992
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $12,063.60 10/03/2025 Non-covered Recipient Entity
Arizona Liver Health
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) No dispute reported 06/30/2026 1184285695
Principal investigator 1 Madrigal Pharmaceuticals $8,939.03 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251186
Principal investigator 1 Madrigal Pharmaceuticals $500.00 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251195
Principal investigator 1 Madrigal Pharmaceuticals $450.00 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251198
Principal investigator 1 Madrigal Pharmaceuticals $750.00 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251203
Principal investigator 1 Madrigal Pharmaceuticals $1,012.50 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251206
Principal investigator 1 Madrigal Pharmaceuticals $12,740.07 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248251211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $996.55 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,945.95 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244507
Principal investigator 1 Madrigal Pharmaceuticals $292.50 10/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250830
Principal investigator 1 Madrigal Pharmaceuticals $305.50 10/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250835
Principal investigator 1 Madrigal Pharmaceuticals $21,526.25 10/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250842
Principal investigator 1 Madrigal Pharmaceuticals $175.00 10/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250847
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694597
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694599
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694601
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694603
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694605
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694607
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766374
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,075.00 10/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220801984
Principal investigator 1 ModernaTX, Inc. $14,676.30 09/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999077
Principal investigator 1 ModernaTX, Inc. $8,325.90 09/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999141
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684895
Principal investigator 1 Boehringer Ingelheim International GmbH $1,576.40 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684897
Principal investigator 1 Boehringer Ingelheim International GmbH $5,483.80 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684899
Principal investigator 1 Boehringer Ingelheim International GmbH $1,576.40 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684903
Principal investigator 1 Boehringer Ingelheim International GmbH $10,263.40 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684909
Principal investigator 1 Boehringer Ingelheim International GmbH $5,483.80 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684911
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684919
Principal investigator 1 Boehringer Ingelheim International GmbH $10,263.40 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684923
Principal investigator 1 Boehringer Ingelheim International GmbH $5,384.40 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684925
Principal investigator 1 Boehringer Ingelheim International GmbH $4,600.40 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684927
Principal investigator 1 Boehringer Ingelheim International GmbH $1,576.40 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684935
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 09/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684941
Principal investigator 1 GlaxoSmithKline, LLC. $4,976.02 09/26/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192156085
Principal investigator 1 ModernaTX, Inc. $1,757.03 09/26/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975905
Principal investigator 1 GlaxoSmithKline, LLC. $8,538.60 09/25/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153181
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 09/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684893
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 09/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684913
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 09/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684915
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 09/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684917
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 09/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699508
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 09/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699586
Principal investigator 1 Madrigal Pharmaceuticals $13,416.00 09/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250716
Principal investigator 1 ModernaTX, Inc. $45.50 09/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999025
Principal investigator 1 ModernaTX, Inc. $151.20 09/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999031
Principal investigator 1 ModernaTX, Inc. $117.00 09/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999033
Principal investigator 1 Madrigal Pharmaceuticals $6,784.43 09/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250637
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,170.40 09/22/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801968
Principal investigator 1 Madrigal Pharmaceuticals $1,281.80 09/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250469
Principal investigator 1 Madrigal Pharmaceuticals $97.50 09/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250474
Principal investigator 1 Madrigal Pharmaceuticals $2,100.00 09/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250478
Principal investigator 1 Madrigal Pharmaceuticals $3,250.80 09/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250482
Principal investigator 1 ModernaTX, Inc. $884.25 09/19/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975891
Principal investigator 1 ModernaTX, Inc. $4,419.52 09/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999063
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,133.30 09/18/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801966
Principal investigator 1 Madrigal Pharmaceuticals $11,093.63 09/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,015.50 09/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184240838
Principal investigator 1 Boehringer Ingelheim International GmbH $450.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684901
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684905
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684907
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684921
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684929
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684931
Principal investigator 1 Boehringer Ingelheim International GmbH $470.40 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684933
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684937
Principal investigator 1 Boehringer Ingelheim International GmbH $329.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684939
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684943
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 09/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684945
Principal investigator 1 Madrigal Pharmaceuticals $96,565.00 09/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250087
Principal investigator 1 Madrigal Pharmaceuticals $4,690.00 09/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250079
Principal investigator 1 F. Hoffmann-La Roche AG $2,225.00 09/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665819
Principal investigator 1 F. Hoffmann-La Roche AG $50.00 09/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665848
Principal investigator 1 F. Hoffmann-La Roche AG $3,010.00 09/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665857
Principal investigator 1 F. Hoffmann-La Roche AG $4,500.00 09/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665771
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 09/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 09/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $566.30 09/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236095
Principal investigator 1 Madrigal Pharmaceuticals $487.50 09/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249782
Principal investigator 1 Madrigal Pharmaceuticals $4,277.00 09/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249786
Principal investigator 1 Madrigal Pharmaceuticals $9,259.66 09/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249658
Principal investigator 1 Madrigal Pharmaceuticals $15,973.20 09/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249667
Principal investigator 1 Madrigal Pharmaceuticals $135.00 09/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249672
Principal investigator 1 Madrigal Pharmaceuticals $15,255.00 09/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249676
Principal investigator 1 ModernaTX, Inc. $3,074.40 09/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999067
Principal investigator 1 ModernaTX, Inc. $273.00 09/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011592
Principal investigator 1 ModernaTX, Inc. $627.90 09/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011596
Principal investigator 1 ModernaTX, Inc. $23,577.29 09/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011612
Principal investigator 1 ModernaTX, Inc. $28,509.00 09/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011634
Principal investigator 1 Madrigal Pharmaceuticals $700.00 09/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249373
Principal investigator 1 Madrigal Pharmaceuticals $12,110.00 09/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249377
Principal investigator 1 Madrigal Pharmaceuticals $13,664.00 09/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249381
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694557
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694569
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694571
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694573
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694575
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694577
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694593
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766368
Principal investigator 1 F. Hoffmann-La Roche AG $4,760.10 09/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665837
Principal investigator 1 Madrigal Pharmaceuticals $27,690.00 09/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249323
Principal investigator 1 Madrigal Pharmaceuticals $13,928.60 09/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249327
Principal investigator 1 ModernaTX, Inc. $627.90 09/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011586
Principal investigator 1 Boehringer Ingelheim International GmbH $4,159.40 08/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684863
Principal investigator 1 Boehringer Ingelheim International GmbH $2,804.20 08/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684865
Principal investigator 1 Boehringer Ingelheim International GmbH $1,576.40 08/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684867
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 08/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684869
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 08/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684871
Principal investigator 1 Boehringer Ingelheim International GmbH $5,384.40 08/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684873
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $733.60 08/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801964
Principal investigator 1 ModernaTX, Inc. $43,000.40 08/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999055
Principal investigator 1 ModernaTX, Inc. $7,827.36 08/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999057
Principal investigator 1 ModernaTX, Inc. $2,920.68 08/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999151
Principal investigator 1 ModernaTX, Inc. $9,799.68 08/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999161
Principal investigator 1 ModernaTX, Inc. $573.04 08/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011610
Principal investigator 1 ModernaTX, Inc. $1,408.72 08/27/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975901
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684875
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684877
Principal investigator 1 Boehringer Ingelheim International GmbH $549.63 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684879
Principal investigator 1 Boehringer Ingelheim International GmbH $262.20 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684881
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684883
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684885
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684887
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684889
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 08/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684891
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699506
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 08/26/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760751
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 08/26/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760753
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 08/26/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760755
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 08/26/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760757
Principal investigator 1 Boehringer Ingelheim International GmbH $1.85 08/26/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760759
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 08/26/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760761
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766370
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766372
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 08/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249193
Principal investigator 1 Madrigal Pharmaceuticals $11,745.00 08/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249201
Principal investigator 1 Madrigal Pharmaceuticals $1,312.50 08/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249204
Principal investigator 1 F. Hoffmann-La Roche AG $1,936.00 08/25/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665852
Principal investigator 1 ModernaTX, Inc. $27,846.00 08/25/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011584
Principal investigator 1 ModernaTX, Inc. $455.00 08/25/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011638
Principal investigator 1 ModernaTX, Inc. $16,260.20 08/25/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011646
Principal investigator 1 Madrigal Pharmaceuticals $16,210.61 08/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249020
Principal investigator 1 Madrigal Pharmaceuticals $5,579.60 08/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249023
Principal investigator 1 Madrigal Pharmaceuticals $390.00 08/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249028
Principal investigator 1 Madrigal Pharmaceuticals $682.50 08/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249032
Principal investigator 1 Madrigal Pharmaceuticals $520.00 08/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249036
Principal investigator 1 Madrigal Pharmaceuticals $97.50 08/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249039
Principal investigator 1 Madrigal Pharmaceuticals $11,271.00 08/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249043
Principal investigator 1 GlaxoSmithKline, LLC. $3,618.00 08/21/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192156078
Principal investigator 1 GlaxoSmithKline, LLC. $15,490.00 08/21/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192156537
Principal investigator 1 Madrigal Pharmaceuticals $6,463.80 08/21/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248951
Principal investigator 1 ModernaTX, Inc. $5,525.00 08/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011600
Principal investigator 1 ModernaTX, Inc. $3,252.04 08/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011602
Principal investigator 1 ModernaTX, Inc. $941.85 08/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011636
Principal investigator 1 ModernaTX, Inc. $91.00 08/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011644
Principal investigator 1 F. Hoffmann-La Roche AG $2,350.00 08/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665799
Principal investigator 1 F. Hoffmann-La Roche AG $4,725.00 08/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665822
Principal investigator 1 F. Hoffmann-La Roche AG $12,040.00 08/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665840
Principal investigator 1 F. Hoffmann-La Roche AG $3,710.00 08/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665861
Principal investigator 1 Madrigal Pharmaceuticals $12,317.50 08/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248795
Principal investigator 1 Madrigal Pharmaceuticals $195.00 08/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248800
Principal investigator 1 Madrigal Pharmaceuticals $13,221.00 08/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248770
Principal investigator 1 Madrigal Pharmaceuticals $2,609.89 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248536
Principal investigator 1 Madrigal Pharmaceuticals $4,050.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248617
Principal investigator 1 Madrigal Pharmaceuticals $405.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248621
Principal investigator 1 Madrigal Pharmaceuticals $38,272.50 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248625
Principal investigator 1 Madrigal Pharmaceuticals $540.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248630
Principal investigator 1 Madrigal Pharmaceuticals $4,455.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248634
Principal investigator 1 Madrigal Pharmaceuticals $38,272.50 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248639
Principal investigator 1 Madrigal Pharmaceuticals $2,018.25 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248644
Principal investigator 1 Madrigal Pharmaceuticals $25,515.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248647
Principal investigator 1 Madrigal Pharmaceuticals $3,915.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248651
Principal investigator 1 Madrigal Pharmaceuticals $540.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248656
Principal investigator 1 Madrigal Pharmaceuticals $25,515.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248660
Principal investigator 1 Madrigal Pharmaceuticals $810.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248665
Principal investigator 1 Madrigal Pharmaceuticals $3,780.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248669
Principal investigator 1 Madrigal Pharmaceuticals $5,062.50 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248672
Principal investigator 1 Madrigal Pharmaceuticals $250.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248676
Principal investigator 1 Madrigal Pharmaceuticals $1,080.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248680
Principal investigator 1 Madrigal Pharmaceuticals $70,807.50 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248683
Principal investigator 1 Madrigal Pharmaceuticals $21,735.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248688
Principal investigator 1 Madrigal Pharmaceuticals $270.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248692
Principal investigator 1 Madrigal Pharmaceuticals $50.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248696
Principal investigator 1 F. Hoffmann-La Roche AG $5,899.50 08/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665779
Principal investigator 1 F. Hoffmann-La Roche AG $3,510.00 08/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665792
Principal investigator 1 ModernaTX, Inc. $1,102.95 08/08/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975897
Principal investigator 1 AstraZeneca UK Limited $129,895.90 08/06/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH II LLC
A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA No dispute reported 06/30/2026 1185541076
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,102.35 08/06/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801962
Principal investigator 1 ModernaTX, Inc. $3,276.00 08/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999155
Principal investigator 1 Dexcom, Inc. $1,395.00 08/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962266
Principal investigator 1 Dexcom, Inc. $2,500.00 08/05/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962268
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694559
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694561
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694563
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694565
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694567
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694591
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766360
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766362
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766364
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
Arizona Clinical Trials-Tucson
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220766366
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $600.00 07/31/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801958
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 07/31/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801960
Principal investigator 1 F. Hoffmann-La Roche AG $1,936.00 07/31/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665806
Principal investigator 1 F. Hoffmann-La Roche AG $1,842.75 07/31/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665810
Principal investigator 1 Madrigal Pharmaceuticals $6,919.09 07/31/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247914
Principal investigator 1 Boehringer Ingelheim International GmbH $2,804.20 07/30/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684855
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 07/30/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684857
Principal investigator 1 Boehringer Ingelheim International GmbH $1,960.00 07/30/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684859
Principal investigator 1 Boehringer Ingelheim International GmbH $4,159.40 07/30/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684861
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694595
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760739
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760741
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760743
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760745
Principal investigator 1 Boehringer Ingelheim International GmbH $1.85 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760747
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220760749
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $380.00 07/28/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802718
Principal investigator 1 ModernaTX, Inc. $2,150.02 07/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999051
Principal investigator 1 ModernaTX, Inc. $2,507.34 07/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999135
Principal investigator 1 ModernaTX, Inc. $978.42 07/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999143
Principal investigator 1 ModernaTX, Inc. $19.76 07/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011588
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,690.00 07/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801956
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 07/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802716
Principal investigator 1 ModernaTX, Inc. $2,100.00 07/25/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975875
Principal investigator 1 ModernaTX, Inc. $900.00 07/25/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975877
Principal investigator 1 ModernaTX, Inc. $1,757.03 07/25/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975879
Principal investigator 1 ModernaTX, Inc. $500.00 07/25/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975881
Principal investigator 1 ModernaTX, Inc. $1,500.00 07/25/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975909
Principal investigator 1 ModernaTX, Inc. $1,262.72 07/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999095
Principal investigator 1 ModernaTX, Inc. $1,053.00 07/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,139.50 07/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,346.25 07/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.75 07/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,336.50 07/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.00 07/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217569
Principal investigator 1 Madrigal Pharmaceuticals $34,941.85 07/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247293
Principal investigator 1 Madrigal Pharmaceuticals $5,782.40 07/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247297
Principal investigator 1 Madrigal Pharmaceuticals $390.00 07/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247300
Principal investigator 1 Ipsen Bioscience Inc. $1,179.71 07/17/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545577
Principal investigator 1 Madrigal Pharmaceuticals $2,018.25 07/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247200
Principal investigator 1 Madrigal Pharmaceuticals $700.00 07/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247204
Principal investigator 1 Madrigal Pharmaceuticals $300.00 07/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247208
Principal investigator 1 Madrigal Pharmaceuticals $7,207.50 07/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 07/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184216964
Principal investigator 1 Madrigal Pharmaceuticals $682.50 07/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247081
Principal investigator 1 Madrigal Pharmaceuticals $3,179.80 07/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247085
Principal investigator 1 Madrigal Pharmaceuticals $29,022.50 07/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247089
Principal investigator 1 Madrigal Pharmaceuticals $195.00 07/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247093
Principal investigator 1 GlaxoSmithKline, LLC. $3,455.34 07/14/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192185666
Principal investigator 1 Madrigal Pharmaceuticals $9,394.32 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246953
Principal investigator 1 Madrigal Pharmaceuticals $48,358.50 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,126.25 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184214228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.00 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184214230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.35 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184214232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $675.00 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184214234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $996.55 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184214654
Principal investigator 1 ModernaTX, Inc. $8,190.00 07/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975895
Principal investigator 1 F. Hoffmann-La Roche AG $80,519.40 07/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665786
Principal investigator 1 F. Hoffmann-La Roche AG $7,020.00 07/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665795
Principal investigator 1 F. Hoffmann-La Roche AG $50.00 07/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665815
Principal investigator 1 F. Hoffmann-La Roche AG $2,550.00 07/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665833
Principal investigator 1 F. Hoffmann-La Roche AG $2,000.00 07/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665844
Principal investigator 1 Madrigal Pharmaceuticals $11,869.55 07/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,211.00 07/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184213129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $159.30 07/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184213131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 07/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184213133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 07/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184213135
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4.00 07/02/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802720
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694579
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694581
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694583
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694585
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694587
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694589
Principal investigator 1 F. Hoffmann-La Roche AG $11,000.00 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665775
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665784
Principal investigator 1 F. Hoffmann-La Roche AG $6,000.00 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665789
Principal investigator 1 F. Hoffmann-La Roche AG $2,000.00 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665802
Principal investigator 1 F. Hoffmann-La Roche AG $43,626.80 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665828
Principal investigator 1 Madrigal Pharmaceuticals $1,363.50 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246273
Principal investigator 1 Madrigal Pharmaceuticals $843.75 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246278
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 06/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684825
Principal investigator 1 Boehringer Ingelheim International GmbH $15,000.00 06/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684831
Principal investigator 1 ModernaTX, Inc. $730.17 06/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999019
Principal investigator 1 ModernaTX, Inc. $6,469.32 06/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999035
Principal investigator 1 ModernaTX, Inc. $16,125.15 06/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999037
Principal investigator 1 ModernaTX, Inc. $13,045.60 06/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999087
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,772.90 06/26/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801954
Principal investigator 1 ModernaTX, Inc. $2,167.43 06/25/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975883
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684821
Principal investigator 1 Boehringer Ingelheim International GmbH $7,000.00 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684823
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.00 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684827
Principal investigator 1 Boehringer Ingelheim International GmbH $9,828.00 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684829
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694555
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699496
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699498
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699500
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699502
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699504
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699576
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699578
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699580
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699582
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 06/24/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220699584
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801952
Principal investigator 1 Madrigal Pharmaceuticals $4,629.83 06/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246084
Principal investigator 1 F. Hoffmann-La Roche AG $127,128.35 06/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211665769
Principal investigator 1 GlaxoSmithKline, LLC. $4,427.00 06/23/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192149703
Principal investigator 1 GlaxoSmithKline, LLC. $7,622.02 06/23/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192156545
Principal investigator 1 Madrigal Pharmaceuticals $4,881.50 06/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245953
Principal investigator 1 Madrigal Pharmaceuticals $877.50 06/20/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245957
Principal investigator 1 Madrigal Pharmaceuticals $4,629.83 06/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,569.75 06/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184209364
Principal investigator 1 Madrigal Pharmaceuticals $390.00 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245754
Principal investigator 1 Madrigal Pharmaceuticals $1,449.50 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245758
Principal investigator 1 ModernaTX, Inc. $2,190.51 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999045
Principal investigator 1 ModernaTX, Inc. $9,570.00 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999081
Principal investigator 1 ModernaTX, Inc. $35,475.33 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999085
Principal investigator 1 ModernaTX, Inc. $18,916.12 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999089
Principal investigator 1 ModernaTX, Inc. $9,636.54 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011626
Principal investigator 1 ModernaTX, Inc. $1,823.97 06/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011640
Principal investigator 1 Madrigal Pharmaceuticals $13,657.86 06/13/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245619
Principal investigator 1 Madrigal Pharmaceuticals $9,394.32 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245377
Principal investigator 1 Madrigal Pharmaceuticals $50.00 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245396
Principal investigator 1 Madrigal Pharmaceuticals $4,036.50 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245400
Principal investigator 1 Madrigal Pharmaceuticals $250.00 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245404
Principal investigator 1 Madrigal Pharmaceuticals $3,037.50 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245408
Principal investigator 1 Madrigal Pharmaceuticals $2,609.89 06/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,011.15 06/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,139.50 06/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204461
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694533
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694535
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694537
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694539
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694541
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694543
Principal investigator 1 GlaxoSmithKline, LLC. $420.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149698
Principal investigator 1 GlaxoSmithKline, LLC. $490.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149720
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153158
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153166
Principal investigator 1 GlaxoSmithKline, LLC. $560.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153169
Principal investigator 1 GlaxoSmithKline, LLC. $42.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153173
Principal investigator 1 GlaxoSmithKline, LLC. $42.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153185
Principal investigator 1 GlaxoSmithKline, LLC. $42.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156068
Principal investigator 1 GlaxoSmithKline, LLC. $176.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156097
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156550
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156553
Principal investigator 1 GlaxoSmithKline, LLC. $420.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192185647
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192185654
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 05/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192185670
Principal investigator 1 Boehringer Ingelheim International GmbH $3,216.50 05/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684833
Principal investigator 1 Madrigal Pharmaceuticals $13,591.50 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244602
Principal investigator 1 Madrigal Pharmaceuticals $487.50 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244607
Principal investigator 1 Madrigal Pharmaceuticals $5,085.12 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244616
Principal investigator 1 Madrigal Pharmaceuticals $250.00 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244640
Principal investigator 1 Madrigal Pharmaceuticals $3,037.50 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244643
Principal investigator 1 ModernaTX, Inc. $1,757.03 05/28/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975889
Principal investigator 1 ModernaTX, Inc. $37,625.35 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999023
Principal investigator 1 ModernaTX, Inc. $32,940.14 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999047
Principal investigator 1 ModernaTX, Inc. $9,474.30 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999137
Principal investigator 1 ModernaTX, Inc. $55,011.84 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011594
Principal investigator 1 ModernaTX, Inc. $255,577.80 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011628
Principal investigator 1 ModernaTX, Inc. $29,183.52 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,969.70 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184199127
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 05/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694549
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 05/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694551
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 05/27/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694553
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,480.00 05/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801950
Principal investigator 1 ModernaTX, Inc. $5,050.88 05/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999107
Principal investigator 1 Madrigal Pharmaceuticals $9,779.08 05/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244272
Principal investigator 1 Madrigal Pharmaceuticals $4,090.00 05/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244280
Principal investigator 1 Madrigal Pharmaceuticals $1,350.00 05/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244284
Principal investigator 1 Madrigal Pharmaceuticals $450.00 05/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244288
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699478
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699480
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699482
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699484
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699486
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699488
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699490
Principal investigator 1 Boehringer Ingelheim International GmbH $195.00 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699492
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 05/20/2025 Non-covered Recipient Entity
Arizona Liver Health-Peoria Liver Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220699494
Principal investigator 1 Dexcom, Inc. $28,091.70 05/20/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962262
Principal investigator 1 GlaxoSmithKline, LLC. $3,767.89 05/19/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156525
Principal investigator 1 Madrigal Pharmaceuticals $390.00 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243765
Principal investigator 1 Madrigal Pharmaceuticals $149.50 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243769
Principal investigator 1 Madrigal Pharmaceuticals $20,231.46 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243777
Principal investigator 1 Madrigal Pharmaceuticals $540.00 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243784
Principal investigator 1 Madrigal Pharmaceuticals $3,240.00 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184195001
Principal investigator 1 Dexcom, Inc. $8,667.75 05/13/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962264
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,171.50 05/09/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801948
Principal investigator 1 GlaxoSmithKline, LLC. $420.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149706
Principal investigator 1 GlaxoSmithKline, LLC. $42.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149710
Principal investigator 1 GlaxoSmithKline, LLC. $42.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149715
Principal investigator 1 GlaxoSmithKline, LLC. $907.20 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149724
Principal investigator 1 GlaxoSmithKline, LLC. $44.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153162
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192153177
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156082
Principal investigator 1 GlaxoSmithKline, LLC. $280.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156089
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156102
Principal investigator 1 GlaxoSmithKline, LLC. $420.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156541
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192185643
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 05/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192185657
Principal investigator 1 Ipsen Bioscience Inc. $2,319.52 05/08/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545575
Principal investigator 1 ModernaTX, Inc. $116.55 05/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999017
Principal investigator 1 ModernaTX, Inc. $273.00 05/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999039
Principal investigator 1 ModernaTX, Inc. $806.40 05/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999101
Principal investigator 1 ModernaTX, Inc. $585.00 05/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999165
Principal investigator 1 Madrigal Pharmaceuticals $303.75 05/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248243205
Principal investigator 1 Madrigal Pharmaceuticals $3,993.30 05/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248243209
Principal investigator 1 Madrigal Pharmaceuticals $5,560.91 05/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248243166
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $304.00 05/02/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802710
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $32.00 05/02/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802712
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4.00 05/02/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802714
Principal investigator 1 Madrigal Pharmaceuticals $3,009.69 05/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243023
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694521
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694523
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694525
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694527
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694529
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694531
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,635.00 05/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801942
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,740.00 05/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801944
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $335.00 05/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801946
Principal investigator 1 ModernaTX, Inc. $3,103.65 05/01/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975887
Principal investigator 1 Madrigal Pharmaceuticals $42,619.50 04/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248242919
Principal investigator 1 Madrigal Pharmaceuticals $4,090.00 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242778
Principal investigator 1 Madrigal Pharmaceuticals $400.00 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242782
Principal investigator 1 Madrigal Pharmaceuticals $19,019.44 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248242789
Principal investigator 1 ModernaTX, Inc. $38,810.66 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999021
Principal investigator 1 ModernaTX, Inc. $1,062.17 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999029
Principal investigator 1 ModernaTX, Inc. $8,632.14 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999049
Principal investigator 1 ModernaTX, Inc. $1,460.34 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999069
Principal investigator 1 ModernaTX, Inc. $2,979.66 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999111
Principal investigator 1 ModernaTX, Inc. $93,022.47 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011582
Principal investigator 1 ModernaTX, Inc. $1,256.94 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011650
Principal investigator 1 ModernaTX, Inc. $82,754.88 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011652
Principal investigator 1 Boehringer Ingelheim International GmbH $1,742.25 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684835
Principal investigator 1 Boehringer Ingelheim International GmbH $766.50 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684837
Principal investigator 1 Boehringer Ingelheim International GmbH $1,221.40 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684839
Principal investigator 1 Boehringer Ingelheim International GmbH $437.00 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684841
Principal investigator 1 Boehringer Ingelheim International GmbH $27.00 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684843
Principal investigator 1 Boehringer Ingelheim International GmbH $106.47 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684845
Principal investigator 1 Boehringer Ingelheim International GmbH $106.47 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684847
Principal investigator 1 Boehringer Ingelheim International GmbH $106.47 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684849
Principal investigator 1 Boehringer Ingelheim International GmbH $106.47 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684851
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 04/23/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684853
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 04/23/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694545
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 04/23/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694547
Principal investigator 1 Madrigal Pharmaceuticals $21,067.86 04/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242573
Principal investigator 1 ModernaTX, Inc. $3,156.80 04/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999083
Principal investigator 1 Dexcom, Inc. $3,200.00 04/15/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962258
Principal investigator 1 Dexcom, Inc. $23,888.62 04/15/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962260
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,011.15 04/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184183264
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 04/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184183266
Principal investigator 1 GlaxoSmithKline, LLC. $14,454.44 04/10/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156073
Principal investigator 1 Madrigal Pharmaceuticals $6,054.75 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242060
Principal investigator 1 Madrigal Pharmaceuticals $50.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242064
Principal investigator 1 Madrigal Pharmaceuticals $150.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242068
Principal investigator 1 Madrigal Pharmaceuticals $250.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242072
Principal investigator 1 Madrigal Pharmaceuticals $1,052.50 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242077
Principal investigator 1 Madrigal Pharmaceuticals $300.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242081
Principal investigator 1 Madrigal Pharmaceuticals $200.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242085
Principal investigator 1 Madrigal Pharmaceuticals $135.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242089
Principal investigator 1 Madrigal Pharmaceuticals $14,242.50 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242092
Principal investigator 1 Eli Lilly and Company $1,962.67 04/08/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187883552
Principal investigator 1 Madrigal Pharmaceuticals $22,905.47 04/08/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241812
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694509
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694511
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694513
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694515
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694517
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694519
Principal investigator 1 ModernaTX, Inc. $3,784.05 04/01/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $996.55 04/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184180610
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 03/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694501
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 03/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694503
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 03/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694505
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31,720.50 03/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801940
Principal investigator 1 ModernaTX, Inc. $2,327.48 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999053
Principal investigator 1 ModernaTX, Inc. $2,190.51 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999065
Principal investigator 1 ModernaTX, Inc. $28,048.04 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999079
Principal investigator 1 ModernaTX, Inc. $8,555.58 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999113
Principal investigator 1 ModernaTX, Inc. $1,499.48 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999115
Principal investigator 1 ModernaTX, Inc. $39,300.29 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999125
Principal investigator 1 ModernaTX, Inc. $61,171.08 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011598
Principal investigator 1 ModernaTX, Inc. $67,486.89 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011606
Principal investigator 1 ModernaTX, Inc. $75,325.12 03/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011654
Principal investigator 1 GlaxoSmithKline, LLC. $5,104.54 03/21/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156533
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 03/21/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192185675
Principal investigator 1 ModernaTX, Inc. $6,667.00 03/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011616
Principal investigator 1 ModernaTX, Inc. $1,881.00 03/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011618
Principal investigator 1 ModernaTX, Inc. $500.00 03/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 03/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184174312
Principal investigator 1 Madrigal Pharmaceuticals $13,814.75 03/14/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241029
Principal investigator 1 Madrigal Pharmaceuticals $4,877.50 03/13/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240879
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.00 03/12/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,488.60 03/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184170718
Principal investigator 1 Madrigal Pharmaceuticals $62,328.19 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240240
Principal investigator 1 Dexcom, Inc. $4,921.00 03/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962256
Principal investigator 1 Eli Lilly and Company $29,216.00 03/04/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187881618
Principal investigator 1 Madrigal Pharmaceuticals $1,254.50 03/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248240084
Principal investigator 1 Madrigal Pharmaceuticals $390.00 03/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248240088
Principal investigator 1 ModernaTX, Inc. $1,757.03 03/03/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975903
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694481
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694483
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694485
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694487
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694489
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694491
Principal investigator 1 ModernaTX, Inc. $2,190.51 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999013
Principal investigator 1 ModernaTX, Inc. $10,603.56 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999071
Principal investigator 1 ModernaTX, Inc. $9,359.46 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999123
Principal investigator 1 ModernaTX, Inc. $131,105.04 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999147
Principal investigator 1 ModernaTX, Inc. $10,621.70 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999149
Principal investigator 1 ModernaTX, Inc. $39,136.80 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999163
Principal investigator 1 ModernaTX, Inc. $83,406.96 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011580
Principal investigator 1 ModernaTX, Inc. $150,413.82 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011604
Principal investigator 1 ModernaTX, Inc. $105,790.26 02/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011624
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 02/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694493
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694495
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 02/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694497
Principal investigator 1 Boehringer Ingelheim International GmbH $27.60 02/25/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,552.75 02/25/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184155578
Principal investigator 1 GlaxoSmithKline, LLC. $3,186.00 02/24/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192153189
Principal investigator 1 GlaxoSmithKline, LLC. $3,186.00 02/24/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192156093
Principal investigator 1 GlaxoSmithKline, LLC. $13,010.06 02/24/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192156519
Principal investigator 1 Dexcom, Inc. $20,649.00 02/18/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962250
Principal investigator 1 Eli Lilly and Company $184,160.00 02/18/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,053.35 02/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 02/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.00 02/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154582
Principal investigator 1 Madrigal Pharmaceuticals $1,170.00 02/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239835
Principal investigator 1 Madrigal Pharmaceuticals $7,215.00 02/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239839
Principal investigator 1 Madrigal Pharmaceuticals $17,296.50 02/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239843
Principal investigator 1 Madrigal Pharmaceuticals $1,267.50 02/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239847
Principal investigator 1 AstraZeneca UK Limited $19,726.00 02/12/2025 Non-covered Recipient Entity
ARIZONA CLINICAL TRIALS
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185541074
Principal investigator 1 Madrigal Pharmaceuticals $32,805.00 02/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239069
Principal investigator 1 Madrigal Pharmaceuticals $29,310.21 02/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,484.85 02/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184152554
Principal investigator 1 Dexcom, Inc. $2,540.00 02/04/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962254
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694469
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694471
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694473
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694475
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694477
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694479
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187881610
Principal investigator 1 Eli Lilly and Company $6,152.64 01/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882160
Principal investigator 1 Eli Lilly and Company $3,859.02 01/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187883856
Principal investigator 1 ModernaTX, Inc. $2,167.43 01/29/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975899
Principal investigator 1 ModernaTX, Inc. $604.89 01/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999015
Principal investigator 1 ModernaTX, Inc. $136.50 01/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999027
Principal investigator 1 ModernaTX, Inc. $702.00 01/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999043
Principal investigator 1 ModernaTX, Inc. $2,525.44 01/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999097
Principal investigator 1 ModernaTX, Inc. $313.95 01/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999119
Principal investigator 1 ModernaTX, Inc. $50.40 01/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999139
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 01/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801934
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.00 01/28/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801936
Principal investigator 1 Eli Lilly and Company $80,677.00 01/28/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882072
Principal investigator 1 GlaxoSmithKline, LLC. $17,024.00 01/28/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192185651
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,594.55 01/27/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801932
Principal investigator 1 ModernaTX, Inc. $30,802.93 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999041
Principal investigator 1 ModernaTX, Inc. $17,877.96 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999059
Principal investigator 1 ModernaTX, Inc. $9,131.92 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999075
Principal investigator 1 ModernaTX, Inc. $2,327.48 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999117
Principal investigator 1 ModernaTX, Inc. $3,923.70 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999131
Principal investigator 1 ModernaTX, Inc. $1,499.48 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999145
Principal investigator 1 ModernaTX, Inc. $765.60 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252999153
Principal investigator 1 ModernaTX, Inc. $134,407.50 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011590
Principal investigator 1 ModernaTX, Inc. $3,861.78 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011608
Principal investigator 1 ModernaTX, Inc. $3,351.84 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011614
Principal investigator 1 ModernaTX, Inc. $57,402.80 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011620
Principal investigator 1 ModernaTX, Inc. $107,614.23 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011622
Principal investigator 1 ModernaTX, Inc. $21,607.52 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011630
Principal investigator 1 ModernaTX, Inc. $1,728.20 01/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011648
Principal investigator 1 Boehringer Ingelheim International GmbH $648.00 01/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220684819
Principal investigator 1 Madrigal Pharmaceuticals $10,752.50 01/23/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238727
Principal investigator 1 Eli Lilly and Company $1,201.90 01/22/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881814
Principal investigator 1 Eli Lilly and Company $2,898.18 01/22/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881818
Principal investigator 1 Eli Lilly and Company $64,556.00 01/21/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882070
Principal investigator 1 Eli Lilly and Company $29,885.00 01/21/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187884008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,932.40 01/21/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149194
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,226.20 01/17/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,569.75 01/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,000.00 01/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,066.00 01/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,200.00 01/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 01/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,552.75 01/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184147525
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $77.00 01/09/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802704
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $32.00 01/09/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802706
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $228.00 01/09/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802708
Principal investigator 1 Eli Lilly and Company $8,631.17 01/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187881614
Principal investigator 1 Madrigal Pharmaceuticals $11,576.25 01/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238171
Principal investigator 1 Madrigal Pharmaceuticals $911.25 01/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238175
Principal investigator 1 Madrigal Pharmaceuticals $16,672.50 01/09/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238326
Principal investigator 1 Madrigal Pharmaceuticals $5,312.50 01/09/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238329
Principal investigator 1 Madrigal Pharmaceuticals $1,552.50 01/09/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238334
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,802.04 01/08/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele No dispute reported 06/30/2026 1185541072
Principal investigator 1 Dexcom, Inc. $37,066.00 01/07/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE No dispute reported 06/30/2026 1250962252
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,880.00 01/06/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801930
Principal investigator 1 Eli Lilly and Company $23,793.00 01/06/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187882156
Principal investigator 1 Madrigal Pharmaceuticals $3,647.42 01/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238063
Principal investigator 1 Madrigal Pharmaceuticals $3,009.69 01/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237919
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694459
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694461
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694463
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694465
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694467
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Arizona Liver Health-Tucson Liver Clinic
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220694507